摘要
目的评价CT导向下125I粒子植入术治疗晚期恶性肿瘤的临床价值。方法共108例晚期肿瘤患者接受放射性125I粒子植入术治疗。术前采用治疗计划系统(TPS)计算后布源,术中将活度为0.76~0.84mCi的125I粒子在CT导向下植入肿瘤内。粒子按照1.0~1.5cm平面插植。肿瘤周边匹配剂量(MPD)100~150Gy,每例患者植入10~100颗粒子。2个月后CT复查评价疗效。结果完全缓解23例,部分缓解56例,稳定16例,进展13例。客观应答率(responserate,RR)为73.14%。经随访发现,大多数毒性反应轻微并可耐受,未见出血、胆瘘、胰瘘、腹膜炎等严重并发症。结论CT导向下125I粒子植入术治疗晚期恶性肿瘤疗效确切、创伤小、并发症发生率低。
Objective To evaluate the clinical value of CT guided radioactive ^125I implantation in treating advanced stage malignant tumors. Methods 108 patients with advanced cancers were given radioactive ^125I implantation treatment.According to treatment planning system before the operation,^125I of 0.76-0.84 mCi was implanted into tumor reginns at a distance of 1.0 to 1.5 cm. Matching perimeter dosage （MPD） was in the range from 100 to 150 Gy,and the number of radioactive particles in one patient was in the range from 10 to 100.Two months Later, computer tomography was carried out to evaluate response. Results There were complete response in 23 eases, partial response in 56, stable disease in 16 and progressive disease in 13. The response rate was 73.14%. During follow-up, most toxicity were low-grade and transient, and no other severe complications were seen, such as bleeding, biliary-fistula and pancreatic fistula. Conclusion CT guided radioactive 1^125I implantation therapy was effective with minimal damage and few complications in treating advanced stage malignant tumors.
出处
《白求恩军医学院学报》
2007年第2期74-76,F0004,共4页
Journal of Bethune Military Medical College
